Select Publications
Journal articles
2024, 'WHO global research priorities for antimicrobial resistance in human health', The Lancet Microbe, 5, http://dx.doi.org/10.1016/S2666-5247(24)00134-4
,2024, 'Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone', The Lancet Infectious Diseases, 24, pp. e547 - e548, http://dx.doi.org/10.1016/S1473-3099(24)00486-9
,2024, 'The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization', Journal of Antimicrobial Chemotherapy, 79, pp. 1885 - 1899, http://dx.doi.org/10.1093/jac/dkae176
,2024, 'Global, regional and local surveillance of antimicrobial resistance in Neisseria gonorrhoeae', Microbiology Australia, 45, pp. 138 - 141, http://dx.doi.org/10.1071/MA24038
,2024, 'The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) identifies high levels of ceftriaxone resistance across Vietnam, 2023', The Lancet Regional Health - Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101125
,2024, 'World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme, Cambodia, 2023', Emerging Infectious Diseases, 30, pp. 1493 - 1495, http://dx.doi.org/10.3201/eid3007.240354
,2024, 'Genomic Surveillance of Invasive Meningococcal Disease During a National MenW Outbreak in Australia, 2017-2018', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae249
,2024, 'Australian Gonococcal Surveillance Programme, 1 October to 31 December 2023', Communicable diseases intelligence (2018), 48
,2024, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2023', Communicable diseases intelligence (2018), 48
,2024, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2023', Communicable Diseases Intelligence, http://dx.doi.org/10.33321/cdi.2024.48.21
,2024, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2023', Communicable diseases intelligence (2018), 48
,2024, 'Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2023', Communicable diseases intelligence (2018), 48
,2024, 'Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2023-079144
,2024, 'Defining the phylogenetics and resistome of the major Clostridioides difficile ribotypes circulating in Australia', Microbial Genomics, 10, http://dx.doi.org/10.1099/mgen.0.001232
,2024, 'Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2023-081675
,2024, 'Investigation and response to an outbreak of Neisseria meningitidis serogroup Y ST-1466 urogenital infections, Australia', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.20
,2024, 'High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022-23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)', JAC-Antimicrobial Resistance, 6, http://dx.doi.org/10.1093/jacamr/dlae053
,2024, 'Nocardia species distribution and antimicrobial susceptibility within Australia', Internal Medicine Journal, 54, pp. 613 - 619, http://dx.doi.org/10.1111/imj.16234
,2024, 'Australian Gonococcal Surveillance Programme, 1 April to 30 June 2023', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.13
,2024, 'Australian Gonococcal Surveillance Programme, 1 January to 31 March 2023', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.12
,2024, 'Australian Gonococcal Surveillance Programme, 1 July to 30 September 2023', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.14
,2023, 'Meningococcal Surveillance Australia - Reporting period 1 January to 31 March 2023', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.59
,2023, 'Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype', Journal of Antimicrobial Chemotherapy, 78, pp. 2203 - 2208, http://dx.doi.org/10.1093/jac/dkad221
,2023, 'The Enhanced Gonococcal Surveillance Programme, Cambodia', The Lancet Infectious Diseases, 23, pp. e332 - e333, http://dx.doi.org/10.1016/S1473-3099(23)00479-6
,2023, 'Australian Gonococcal Surveillance Programme Annual Report, 2022', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.45
,2023, 'Australian Meningococcal Surveillance Programme Annual Report, 2022', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.44
,2023, 'Disc Test for Detecting Staphylococcus aureus Strains Producing Type A and Type C b-Lactamases', Microbiology Spectrum, 11, http://dx.doi.org/10.1128/spectrum.00220-23
,2023, 'Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis', The Lancet Infectious Diseases, 23, pp. e268 - e269, http://dx.doi.org/10.1016/S1473-3099(23)00359-6
,2023, 'Antimicrobial susceptibility assays for Neisseria gonorrhoeae: a proof-of-principle population-based retrospective analysis', The Lancet Microbe, 4, pp. e544 - e551, http://dx.doi.org/10.1016/S2666-5247(23)00071-X
,2023, 'Australian Gonococcal Surveillance Programme, 1 April to 30 June 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.28
,2023, 'Australian Gonococcal Surveillance Programme, 1 July to 30 September 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.29
,2023, 'Australian Gonococcal Surveillance Programme, 1 October to 31 December 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.30
,2023, 'Meningococcal Surveillance Australia Reporting period 1 October to 31 December 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.23
,2023, 'Meningococcal Surveillance Australia Reporting period 1 July to 30 September 2022', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.4
,2022, 'Meningococcal Surveillance Australia Reporting period 1 April to 30 June 2022', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.81
,2022, 'Proof-of-concept, rapid, instrument-free molecular detection of Neisseria gonorrhoeae and ciprofloxacin susceptibility', Journal of Antimicrobial Chemotherapy, 77, pp. 2933 - 2936, http://dx.doi.org/10.1093/jac/dkac242
,2022, 'The need for a commercial test using the penA60 allele to identify ceftriaxone-resistant Neisseria gonorrhoeae', The Lancet Infectious Diseases, 22, pp. 1271 - 1272, http://dx.doi.org/10.1016/S1473-3099(22)00520-5
,2022, 'Australian Gonococcal Surveillance Programme Annual Report, 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.52
,2022, 'Australian Gonococcal Surveillance Programme, 1 January to 31 March 2022', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.56
,2022, 'Australian Gonococcal Surveillance Programme, 1 October to 31 December 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.43
,2022, 'Australian Meningococcal Surveillance Programme Annual Report, 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.46
,2022, 'Meningococcal Surveillance Australia Reporting period 1 January to 31 March 2022', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.36
,2022, 'The decline of invasive meningococcal disease and influenza in the time of COVID-19: the silver linings of the pandemic playbook', Medical Journal of Australia, 216, pp. 504 - 507, http://dx.doi.org/10.5694/mja2.51463
,2022, 'Meningococcal Surveillance Australia Reporting period 1 October to 31 December 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.21
,2022, 'A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection among Urban Men Who Have Sex with Men', Journal of Infectious Diseases, 225, pp. 983 - 993, http://dx.doi.org/10.1093/infdis/jiab581
,2022, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.1
,2022, 'Predisposing factors, microbiological features and outcomes of patients with clinical presumed concomitant microbial and herpes simplex keratitis', Eye (Basingstoke), 36, pp. 86 - 94, http://dx.doi.org/10.1038/s41433-021-01440-1
,2021, 'Australian Gonococcal Surveillance Programme 1 April to 30 June 2021', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.68
,2021, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2021', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.63
,2021, 'Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia', PLoS Computational Biology, 17, pp. e1009385, http://dx.doi.org/10.1371/journal.pcbi.1009385
,